Yeji

$BBIO

BridgeBio Pharma, Inc.

Runway:13 mo
NasdaqMarket cap: —CIK 0001743881

Upcoming catalysts

4 surfaced
NDA/BLA filedDate TBD
$BBIOBridgeBio Pharma, Inc.
bbp-418 · LGMD2I/R9 (Limb-Girdle Muscular Dystrophy type 2I/R9)
“BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced the submission of its New Drug Application (NDA) to the FDA for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).”
NDA/BLA filedDate TBD~ low confidence
$BBIOBridgeBio Pharma, Inc.
“BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1”
NDA/BLA filedDate TBD
$BBIOBridgeBio Pharma, Inc.
bbp-418 · LGMD2I/R9 (Limb-Girdle Muscular Dystrophy type 2I/R9)
“BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9”
NDA/BLA filedDate TBD
$BBIOBridgeBio Pharma, Inc.
encaleret · autosomal dominant hypocalcemia type 1 (ADH1)
“today announced the submission of its New Drug Application (NDA) to the FDA for encaleret as a potential targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1).”

Drug pipeline

attruby
bbp-418
LGMD2I/R9 (Limb-Girdle Muscular Dystrophy type 2I/R9)
encaleret
autosomal dominant hypocalcemia type 1 (ADH1)
BBP-398
Solid Tumor, Adult
BBP-398 with nivolumab
Non Small Cell Lung Cancer
BBP-398 (Formerly known as IACS-15509)
Tumor, Solid

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT05480865BBP-398Phase 1Terminated2024-08-22
NCT05375084BBP-398 with nivolumabPhase 1Terminated2024-04-12
NCT04528836BBP-398Phase 1Terminated2024-03-22

Recent catalysts

NDA/BLA filedMay 27, 2026· 10d ago
$BBIOBridgeBio Pharma, Inc.
bbp-418 · LGMD2I/R9 (Limb-Girdle Muscular Dystrophy type 2I/R9)
“On May 27, 2026, BridgeBio Pharma, Inc. issued a press release titled "BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9."”
FDA approvalNov 22, 2024· 561d ago· success
$BBIOBridgeBio Pharma, Inc.
attruby
“openFDA ORIG (TYPE 1) approval of ATTRUBY — application NDA216540”